Updated:
Gain Therapeutics
Gain Therapeutics was founded in 2020 as a spinout from the University of Lugano, built around the computational drug-discovery engine developed by...
Gain Therapeutics
Gain Therapeutics was founded in 2020 as a spinout from the University of Lugano, built around the computational drug-discovery engine developed by co-founder and Chief Scientific Officer Xavier Barril. The firm went public via a SPAC merger in 2021, listing on Nasdaq under the ticker GANX with operations split between Bethesda, Maryland and the original research hub in Lugano, Switzerland. The company's core strategy centers on its SEE-Tx platform, which uses physics-based molecular docking simulations to identify novel allosteric binding sites on misfolded protein targets. This approach has generated a pipeline that includes the lead asset GT-02287, a brain-penetrant glucocerebrosidase regulator in clinical trials for GBA1-mutated Parkinson's disease. The portfolio extends into rare lysosomal storage diseases such as Gaucher and GM1 gangliosidosis, with a 2023 partnership with the Michael J. Fox Foundation providing non-dilutive funding to advance the neurodegeneration program. Geographic focus spans US-based clinical development and European research infrastructure. In March 2024, Gain Therapeutics appointed Gene Mack as permanent CEO following his interim leadership, signaling board confidence in the clinical direction. The 2023 agreement with the Michael J. Fox Foundation is covering a portion of costs for the Phase 1 trial of GT-02287 in Australia, which cleared a safety review committee hurdle and reported initial biomarker data in early 2024 showing target engagement and glucocerebrosidase restoration. The company also maintains a lab collaboration with researchers at the University of Barcelona. Gain Therapeutics occupies a distinct niche as a publicly traded platform-stage biotech where the computational IP remains central — the SEE-Tx engine is positioned not merely as a discovery tool but as a potentially transferable asset that could validate a structural biology thesis across multiple protein-misfolding indications. The dual Swiss-American operating structure provides access to both European academic talent and US capital markets, a geographic arbitrage uncommon among CNS-focused micro-caps.
General information
Firm type
Asset Manager
Year founded
2020
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Bethesda
Corporate office
Bethesda, MD, United States
Additional offices
Lugano, Switzerland
Principals
Gene Mack
Chief Executive Officer
Matthias Alder
Chief Operating Officer
Xavier Barril
Chief Scientific Officer
Sector focus
Frequently asked questions
What is the SEE-Tx platform and how does it differ from traditional drug discovery?
SEE-Tx, or Site-Directed Enzyme Enhancement Therapy, uses physics-based molecular docking simulations to identify novel allosteric binding sites on misfolded proteins. Unlike AI-driven screening that relies on large datasets and pattern recognition, SEE-Tx computationally models the three-dimensional structure of target proteins and simulates small-molecule interactions at a physical level. This allows the team to discover binding pockets that are not evolutionarily conserved and thus not obvious to other drug-discovery approaches.
What does GT-02287 target and where is it in development?
GT-02287 is a brain-penetrant small molecule designed to restore the function of the GCase enzyme, which is encoded by the GBA1 gene and commonly misfolded in patients with GBA1-mutated Parkinson's disease. The compound is in Phase 1 clinical trials, and as of early 2024, an independent safety review committee cleared a cohort to escalate dosing based on favorable safety and biomarker data. The trial is being conducted in Australia with partial funding support from the Michael J. Fox Foundation.
How is Gain Therapeutics funded?
Gain Therapeutics is publicly listed on Nasdaq under the ticker GANX, having gone public via a SPAC merger in 2021. In addition to equity capital, the company secures non-dilutive grant funding for specific programs. A notable example is the partnership with the Michael J. Fox Foundation for Parkinson's Research, which is providing financial support for the clinical development of GT-02287. As a clinical-stage biotech, it remains pre-revenue and relies on periodic equity raises and grants.
Does Gain Therapeutics target only rare diseases?
No. While the company's preclinical programs include rare lysosomal storage disorders like Gaucher disease and GM1 gangliosidosis, its lead clinical asset targets GBA1-mutated Parkinson's disease. This is a significant and genetically defined subset within a common neurodegenerative disorder. The dual focus spans orphan indications and larger CNS populations unified by underlying protein-misfolding pathology.
What is the relationship between the US and Swiss operations?
Gain Therapeutics operates a dual-structure: the corporate and clinical development leadership is based in Bethesda, Maryland, where CEO Gene Mack is located, while the core scientific team and discovery platform remain in Lugano, Switzerland. This model traces back to the company's origin as a University of Lugano spinout. It allows the firm to access European academic collaborators and the US biotech capital markets simultaneously.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: